Novartis Home
At Novartis, we are reimagining medicine
At Novartis, we are reimagining medicine
Navigate Novartis
Alcon becomes a separately traded standalone company
On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.
Visualizing immuno-oncology research
Learn how Novartis researchers are working to outsmart tumors.
Cell & Gene Therapy at Novartis
Our teams aim to deliver on the promise of cell and gene therapy for patients.